Douglas Lane & Associates LLC Lowers Holdings in Haleon plc (NYSE:HLN)

Douglas Lane & Associates LLC trimmed its holdings in Haleon plc (NYSE:HLN) by 0.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 8,462,284 shares of the company’s stock after selling 71,484 shares during the quarter. Haleon accounts for approximately 1.2% of Douglas Lane & Associates LLC’s investment portfolio, making the stock its 26th biggest holding. Douglas Lane & Associates LLC owned 0.19% of Haleon worth $89,531,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Cultivar Capital Inc. purchased a new stake in shares of Haleon during the 2nd quarter worth about $40,000. Allspring Global Investments Holdings LLC purchased a new stake in shares of Haleon during the 1st quarter worth about $43,000. GAMMA Investing LLC boosted its stake in shares of Haleon by 151.3% during the 1st quarter. GAMMA Investing LLC now owns 6,106 shares of the company’s stock worth $52,000 after acquiring an additional 3,676 shares in the last quarter. Pinnacle Bancorp Inc. boosted its stake in shares of Haleon by 29.8% during the 1st quarter. Pinnacle Bancorp Inc. now owns 6,188 shares of the company’s stock worth $53,000 after acquiring an additional 1,421 shares in the last quarter. Finally, Hexagon Capital Partners LLC boosted its stake in shares of Haleon by 66.6% during the 2nd quarter. Hexagon Capital Partners LLC now owns 6,695 shares of the company’s stock worth $55,000 after acquiring an additional 2,677 shares in the last quarter. 6.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on HLN. Berenberg Bank initiated coverage on shares of Haleon in a research note on Tuesday, August 6th. They set a “buy” rating on the stock. The Goldman Sachs Group lowered shares of Haleon from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 6th. UBS Group raised shares of Haleon to a “strong-buy” rating in a research note on Tuesday, October 1st. Finally, Morgan Stanley raised their price target on shares of Haleon from $9.90 to $10.95 and gave the company an “overweight” rating in a research note on Friday, September 20th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Haleon has a consensus rating of “Buy” and an average price target of $10.95.

Haleon Price Performance

HLN stock traded down $0.07 during mid-day trading on Friday, reaching $10.05. The company’s stock had a trading volume of 3,079,115 shares, compared to its average volume of 5,128,434. The stock has a market cap of $45.80 billion, a PE ratio of 33.50, a P/E/G ratio of 2.93 and a beta of 0.26. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. Haleon plc has a fifty-two week low of $7.70 and a fifty-two week high of $10.80. The company’s 50 day moving average is $10.17 and its two-hundred day moving average is $9.08.

Haleon (NYSE:HLN) last released its quarterly earnings data on Thursday, August 1st. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The business had revenue of $3.50 billion during the quarter, compared to analyst estimates of $3.55 billion. Haleon had a net margin of 9.71% and a return on equity of 13.15%. During the same quarter in the previous year, the company posted $0.08 EPS. Equities research analysts expect that Haleon plc will post 0.47 EPS for the current year.

Haleon Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Thursday, September 19th. Shareholders of record on Friday, August 16th were issued a $0.0514 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a yield of 1.6%. Haleon’s payout ratio is 36.67%.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.